Nanotechnology application to local anaesthesia (LA)

Moradkhani, Mahmoud Reza; Karimi, Arash; Negahdari, Babak

doi:10.1080/21691401.2017.1313263

Cited by 29 publications

(21 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposome is a lipid vesicle of nanometer scale, which is phospholipid-based [10]. Liposomal techniques have been long utilized in drug delivery for treating diseases such as cancer, infection, and eye disease.…”

Section: General Ideas About Liposomementioning

confidence: 99%

“…Here, we summarize several state-of-the art formulations of nano-structured extended-release LAs. The most commonly used morphology is nanoparticle, while nano-structured gel, niosome, film, and rod are accessible as well [8,10,11]. Here, synthesis techniques, release profiles, analgesic effects, and safety quality are provided and compared to help future design and development.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Advances of Nano-Structured Extended-Release Local Anesthetics

Qin

Huang

et al. 2020

Nanoscale Res Lett

View full text Add to dashboard Cite

Extended-release local anesthetics (LAs) have drawn increasing attention with their promising role in improving analgesia and reducing adverse events of LAs. Nano-structured carriers such as liposomes and polymersomes optimally meet the demands of/for extended-release, and have been utilized in drug delivery over decades and showed satisfactory results with extended-release. Based on mature technology of liposomes, EXPAREL, the first approved liposomal LA loaded with bupivacaine, has seen its success in an extended-release form. At the same time, polymersomes has advances over liposomes with complementary profiles, which inspires the emergence of hybrid carriers. This article summarized the recent research successes on nano-structured extended-release LAs, of which liposomal and polymeric are mainstream systems. Furthermore, with continual optimization, drug delivery systems carry properties beyond simple transportation, such as specificity and responsiveness. In the near future, we may achieve targeted delivery and controlled-release properties to satisfy various analgesic requirements.

show abstract

Section: General Ideas About Liposomementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Advances of Nano-Structured Extended-Release Local Anesthetics

Qin

Huang

et al. 2020

Nanoscale Res Lett

View full text Add to dashboard Cite

show abstract

“…effects as a method in pain management have been elucidated [64]. In another clinical and preclinical review that focused on the use of nanotechnology for chronic and acute pain management, and surveying both diagnostic and therapeutic uses [65]. Nanomedicine should be developed further by medical practitioners to improve patients healthcare who are constantly living with pain [66].…”

Section: Nanoparticles Application In Pain Reductionmentioning

confidence: 99%

Pain management using nanotechnology approaches

Beiranvand

Sorori

2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

The proper treatment of pain is yet a major medical challenge. To obtain a long-term analgesia action, opioid therapy is the gold standard therapy for overcoming a chronic pain. Nanotechnology focus on formulating therapeutic agents encapsulated in a biocompatible nanocarriers (10-200 nanometer), these include but not limited to nanoparticles, liposomes and nanocapsules, micelles, dendrimers and nanotubes. This review gives an overview of current strategies of pain treatment with the help of the knowledge of nanotechnology. In addition, the applications of nano-innovation in oxidative therapy, genotoxicity and immunogenicity, are elucidated.

show abstract

“…Furthermore Bramlett and co-worker [21] also conducted a phase 2, clinical trial study aimed at evaluating the effectiveness, tolerability and pharmacokinetics of liposomal loaded with bupivacaine compared with plain bupivacaine HCL in total knee arthroplasty patient [22]. A total of 134 patients were used for this study and they were administered with 133 mg of DepoFoam or 150 mg of Bupivacaine HCL.…”

Section: Introductionmentioning

confidence: 99%

Bupivacaine Versus Liposomal Bupivacaine For Pain Control

Beiranvand

Moradkhani

2017

Drug Res (Stuttg)

View full text Add to dashboard Cite

Local infiltrations and regional blocks have been some of the effective ways employed to manage and control post-operative pain. One of the limitations of administration of local anesthesia drugs in post-operative conditions is its inability to act for a longer period of time. Multi-vesicular liposomes made up of bupivacaine have been progressively used for their increased duration of action. Compared to bupivacaine HCL, local infiltration of liposomal bupivacaine have shown to have a significantly increase the duration and delay in peak plasma concentration. In this article, we attempt to compare liposomal bupivacaine and bupivacaine based on available clinical literatures. Liposomal bupivacaine has been demonstrated to have promising implications in post- operative pain control resulting in increased patient satisfaction; reduced hospital admission and opioid induced adverse events. Clinical studies have identified liposomal bupivacaine to be effective in delivering increased post-operative pain control. The purpose of this review is to give a comprehensive comparison between bupivacaine liposomal and conventional bupivacaine based on reported clinical trials.

show abstract

Nanotechnology application to local anaesthesia (LA)

Cited by 29 publications

References 44 publications

Advances of Nano-Structured Extended-Release Local Anesthetics

Advances of Nano-Structured Extended-Release Local Anesthetics

Pain management using nanotechnology approaches

Bupivacaine Versus Liposomal Bupivacaine For Pain Control

Contact Info

Product

Resources

About